FOLH1 and neoplasm: After blocking with NOTA-GC-PSMA, the uptake of 68Ga-NOTA-GC-PSMA in the LNCaP tumor model was reduced (1.05 ± 0.58 %ID/g at 60 min after blocking, p < 0.005) (Figure 5B), indicating that 68Ga-NOTA-GC-PSMA can specifically target PSMA-positive tumors in vivo.